Abstract:
Die Erfindung betrifft einen Mikroorganismen-Stamm der ein AAMT-Gen, ein RLSS-Gen und ein trpE-Gen exprimiert und ein Verfahren, bei dem dieser Mikroorganismen-Stamm in einem Fermentationsmedium fermentiert wird und dabei Methylanthranilat im Kulturüberstand angehäuft wird.
Abstract:
Novel methods that may be used for the manufacture of plant alkaloid compounds and novel polynucleotide compounds are provided. The plant alkaloid compounds are useful as medicinal compounds.
Abstract:
The present invention relates to proteins capable of providing a decorative flowering phenotype in plants and especially in plants belonging to the Kalanchoe genus. The present invention also relates to nucleic acid sequences, or cDNA sequences, and genes encoding the present proteins. The present invention further relates to use of the present proteins, nucleic acid sequences and genes for selecting decorative flowering Kalanchoe plants and decorative flowering Kalanchoe plants comprising the present proteins, mRNA forms of the present cDNAs or the present genes. Specifically, the present invention relates to proteins comprising an amino acid substitution of the amino acid histidine at position 136 and/or the amino acid alanine at position 338 of the methyltransf erase protein of a Kalanchoe plant, wherein the amino acid substitution provides a decorative flowering phenotype in the present Kalanchoe plants.
Abstract:
Objective methods for diagnosing a predisposition to developing cancer are described herein. In one embodiment, the diagnostic method involves determining an expression level of the C1orf59 gene, the PIWIL4 gene, or piRNA and correlating the determined level with a healthy, diseased or at-risk state. The present invention further provides methods of assessing or determining the prognosis of a patient with esophageal cancer. In one embodiment, the diagnostic method involves determining an expression level of the C1orf59 gene. The present invention further provides methods of screening for therapeutic substances useful in the treatment of a C1orf59-, and/or PIWIL4-associated disease, such as a cancer. The present invention further provides methods of treating or preventing a cancer expressing the C1orf59 gene and/or the PIWIL4 gene. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions including them.
Abstract:
CRISPR-Cas genome editing uses a guide RNA, which includes both a complementarity region, which binds the target DNA by base- pairing, and a Cas9-binding region, to direct a Cas9 nuclease to a target DNA. Further disclosed are methods for increasing specificity of RNA-guided genome editing using CRISPR/Cas9 systems by using truncated guide RNAs (tru-gRNAs).
Abstract:
The present invention provides novel protein and gene related to flavonoid O-methyltransferase (FOMT) and their uses therefore. The said protein having an amino acid sequence shown in SEQ ID NO: 3, or an amino acid sequence having deletion, substitution or insertion of one or plural amino acids in said amino acid sequence. The said gene comprising the nucleotide sequence shown in SEQ ID NO: 1, or a gene which hybridizes with said gene under stringent conditions and encodes a protein, which has anthocyanin 3'-O-methyltransferase or 3',5'-O-methyltrasnferase activity. The present invention also provides a method for obtaining the transgenic plant used the above-mentioned gene.
Abstract translation:本发明提供与类黄酮O-甲基转移酶(FOMT)相关的新型蛋白质和基因及其用途。 所述蛋白质具有SEQ ID NO:3所示的氨基酸序列,或在所述氨基酸序列中具有一个或多个氨基酸的缺失,取代或插入的氨基酸序列。 所述基因包含SEQ ID NO:1所示的核苷酸序列,或在严格条件下与所述基因杂交并编码具有花青素3'-O-甲基转移酶或3',5'-O-甲基酪氨酸激酶的蛋白质的基因 活动。 本发明还提供了获得使用上述基因的转基因植物的方法。
Abstract:
The present invention relates to a method of treating T cell mediated inflammatory immune diseases or T cell mediated hypersensitivity diseases, which comprises administering to a human in need thereof an effective amount of a compound which inhibits EZH2 and/or EZH1, or a pharmaceutically acceptable salt thereof.
Abstract:
Vorgeschlagen wird ein Verfahren zur Herstellung von Flavonoiden, umfassend die Schritte: (a) Bereitstellen eines transgenen Mikroorganismus, enthaltend (i) einen ersten Nukleinsäure-Abschnitt (A), umfassend oder bestehend aus einem für eine CYP450-Oxidase kodierenden Gen, (ii) einen zweiten Nukleinsäure-Abschnitt (B), umfassend oder bestehend aus einem für eine pflanzliche O-Methyltransferase kodierenden Gen, sowie (b) Hinzufügen eines oder mehrerer Flavanone zu dem transgenen Mikroorganismus, (c) die Umsetzung der Substrat Flavanone durch des transgenen Mikroorganismus zu den entsprechenden Flavonoiden, sowie gegebenenfalls (d) Isolierung und Aufreinigung der Endprodukte.